\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ and\\ laboratory\\:\\ \ \(0\)\
\-\ patient\\ is\\ tender\\ to\\ palpation\\ over\\ the\\ dip\\ and\\ pip\\ joints\\ in\\ both\\ hands\\.\\ \\ no\\ significant\\ effusions\\ noted\\ over\\ the\\ joint\\ spaces\\.\\ \\ laboratory\\ results\\ reported\\ normal\\ esr\\ levels\ \(0\)\
\-\ treatment\\ and\\ follow\\-up\\:\\ \ \(0\)\
\-\ treatment\\ usually\\ begins\\ with\\ nsaids\\.\\ \\ for\\ more\\ advanced\\ cases\\,\\ or\\ for\\ those\\ not\\ responding\\ to\\ a\\ trial\\ of\\ nsaids\\,\\ dmards\\ such\\ as\\ methotrexate\\ are\\ used\\.\\ \\ anti\\ tnf\\ drugs\\ can\\ also\\ be\\ used\\,\\ as\\ is\\ the\\ case\\ with\\ this\\ patient\\.\\ \\ follow\\-up\\ should\\ include\\ periodic\\ radiographs\\ to\\ assess\\ the\\ progression\\ of\\ the\\ disease\\ and\\ response\\ to\\ therapy\\.\ \(0\)\
\-\ radiographic\\ findings\\:\\ \ \(0\)\
\-\ symmetric\\ joint\\ space\\ loss\\ in\\ the\\ distal\\ interphalangeal\\ joints\\ and\\ proximal\\ interphalangealjoints\\ bilaterally\\.\\ \\ erosions\\ involving\\ the\\ metacarpal\\ heads\\ and\\ fluffy\\ erosions\\ involving\\ the\\ ulnar\\ styloid\\.\\ \\ erosion\\ of\\ the\\ pisiforms\\ bilaterally\\.\\ \\ normal\\ bone\\ mineralization\\ and\\ no\\ remarkable\\ soft\\ tissue\\ changes\ \(0\)\
\-\ diagnosis\\:\ \(12\)\
\-\ psoriatic\\ arthritis\ \(11\)\
\-\ differential\\ diagnosis\\ for\\ these\\ findings\\ in\\ this\\ case\\:\ \(0\)\
\-\ psoriatic\\ arthritis\\,\\ \\ erosive\\ osteoarthritis\ \(0\)\
\-\ history\\ \\(can\\ include\\ gestational\\ age\\,\\ or\\ age\\ in\\ days\\,\\ weeks\\,\\ months\\)\\:\ \(0\)\
\-\ patient\\ with\\ known\\ psoriasis\\,\\ now\\ taking\\ enbrel\\.\\ \\ patient\\ presents\\ with\\ pain\\ and\\ stiffness\\ in\\ both\\ hands\\,\\ made\\ worse\\ by\\ inactivity\\ and\\ relieved\\ somewhat\\ by\\ movement\\.\ \(0\)\
\-\ discussion\\ \\(include\\ references\\)\\:\\ \ \(0\)\
\-\ psoriatic\\ arthritis\\ is\\ an\\ inflammatory\\ arthritis\\ that\\ accompanies\\ psoriasis\\ in\\ up\\ to\\ 30\\%\\ of\\ patients\\ with\\ the\\ disease\\.\\ \\ most\\ patients\\ with\\ psoriatic\\ arthritis\\ are\\ negative\\ for\\ rheumatoid\\ factor\\,\\ but\\ up\\ to\\ 10\\%\\ can\\ be\\ positive\\ for\\ rf\\.\\ \\ psoriatic\\ arthritis\\ affects\\ both\\ sexes\\ equally\\.\\ \\ the\\ clinical\\ presentation\\ is\\ usually\\ of\\ joint\\ pain\\ and\\ stiffness\\ upon\\ awakening\\ and\\ following\\ periods\\ of\\ inactivity\\,\\ alleviated\\ by\\ movement\\.\\ \\ the\\ distribution\\ is\\ often\\ asymmetric\\,\\ and\\ the\\ degree\\ of\\ pain\\ and\\ tenderness\\ is\\ usually\\ less\\ than\\ ra\\.\\ \\ the\\ typical\\ patterns\\ of\\ presentation\\ are\\ polyarthritis\\,\\ similar\\ to\\ ra\\,\\ and\\ oligoarthritis\\,\\ in\\ which\\ less\\ than\\ five\\ joints\\ are\\ affected\\ in\\ an\\ asymmetric\\ fashion\\.\\ \\ mutilating\\ arthritis\\ is\\ not\\ as\\ common\\ as\\ in\\ ra\\.\\ \\ involvement\\ of\\ the\\ dip\\ joints\\ also\\ differentiates\\ pa\\ from\\ ra\\.\ \(0\)\
\-\ gladman\\,\\ dd\\,\\ farewell\\,\\ v\\,\\ buskila\\,\\ d\\,\\ et\\ al\\.\\ reliability\\ of\\ measurements\\ of\\ active\\ and\\ damaged\\ joints\\ in\\ psoriatic\\ arthritis\\.\\ j\\ rheumatol\\ 1990\\;\\ 17\\:62\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ psoriatic\\:\\ 0\\.07966943470881731\ \(0\)\
\-\ arthritis\\:\\ 0\\.07527283402150484\ \(0\)\
\-\ joints\\:\\ 0\\.05038973770010398\ \(0\)\
\-\ ra\\:\\ 0\\.04816890409871099\ \(0\)\
\-\ inactivity\\:\\ 0\\.04186789300725027\ \(0\)\
\-\ psoriasis\\:\\ 0\\.03148179496321798\ \(0\)\
\-\ dip\\:\\ 0\\.02927847529916159\ \(0\)\
\-\ stiffness\\:\\ 0\\.027114280218954043\ \(0\)\
\-\ erosions\\:\\ 0\\.024422582371447312\ \(0\)\
\-\ nsaids\\:\\ 0\\.02376714332255429\ \(0\)\
\-\ hands\\:\\ 0\\.022789016852031233\ \(0\)\
\-\ interphalangealjoints\\:\\ 0\\.022720408309192006\ \(0\)\
\-\ pisiforms\\:\\ 0\\.022720408309192006\ \(0\)\
\-\ oligoarthritis\\:\\ 0\\.022720408309192006\ \(0\)\
\-\ mutilating\\:\\ 0\\.022720408309192006\ \(0\)\
\-\ gladman\\:\\ 0\\.022720408309192006\ \(0\)\
\-\ farewell\\:\\ 0\\.022720408309192006\ \(0\)\
\-\ 17\\:62\\:\\ 0\\.022720408309192006\ \(0\)\
\-\ movement\\:\\ 0\\.022021771348951003\ \(0\)\
\-\ asymmetric\\:\\ 0\\.02140247077244552\ \(0\)\
\-\ joint\\:\\ 0\\.021366721044139805\ \(0\)\
\-\ dmards\\:\\ 0\\.020933946503625137\ \(0\)\
\-\ enbrel\\:\\ 0\\.020933946503625137\ \(0\)\
\-\ accompanies\\:\\ 0\\.020933946503625137\ \(0\)\
\-\ awakening\\:\\ 0\\.020933946503625137\ \(0\)\
\-\ buskila\\:\\ 0\\.020933946503625137\ \(0\)\
\-\ \\:\\:\\ 0\\.02039155595859447\ \(0\)\
\-\ usually\\:\\ 0\\.020063878251547106\ \(0\)\
\-\ tnf\\:\\ 0\\.019888933338397908\ \(0\)\
\-\ polyarthritis\\:\\ 0\\.019888933338397908\ \(0\)\
\-\ sexes\\:\\ 0\\.019147484698058267\ \(0\)\
\-\ rheumatol\\:\\ 0\\.019147484698058267\ \(0\)\
\-\ fluffy\\:\\ 0\\.018572372452403087\ \(0\)\
\-\ dd\\:\\ 0\\.018572372452403087\ \(0\)\
\-\ include\\:\\ 0\\.01853469191775995\ \(0\)\
\-\ anti\\:\\ 0\\.018102471532831038\ \(0\)\
\-\ alleviated\\:\\ 0\\.017361022892491397\ \(0\)\
\-\ differentiates\\:\\ 0\\.017361022892491397\ \(0\)\
\-\ used\\:\\ 0\\.016897856479113203\ \(0\)\
\-\ both\\:\\ 0\\.01687268034035661\ \(0\)\
\-\ reliability\\:\\ 0\\.016785910646836218\ \(0\)\
\-\ responding\\:\\ 0\\.01631600972726417\ \(0\)\
\-\ laboratory\\:\\ 0\\.016232431628113744\ \(0\)\
\-\ damaged\\:\\ 0\\.01591871416069907\ \(0\)\
\-\ periods\\:\\ 0\\.015574561086924527\ \(0\)\
\-\ involving\\:\\ 0\\.01545570754640873\ \(0\)\
\-\ rf\\:\\ 0\\.015418312061624438\ \(0\)\
\-\ styloid\\:\\ 0\\.015270996562036943\ \(0\)\
\-\ presentation\\:\\ 0\\.015172168219026198\ \(0\)\
\-\ interphalangeal\\:\\ 0\\.015131648053608397\ \(0\)\
\-\ can\\:\\ 0\\.0149862553025959\ \(0\)\
\-\ less\\:\\ 0\\.014917216517127229\ \(0\)\
\-\ pip\\:\\ 0\\.014873700995471842\ \(0\)\
\-\ 1990\\:\\ 0\\.014753804047959233\ \(0\)\
\-\ \\,\\:\\ 0\\.014651833442945968\ \(0\)\
\-\ equally\\:\\ 0\\.014639237649580795\ \(0\)\
\-\ measurements\\:\\ 0\\.014639237649580795\ \(0\)\
\-\ fashion\\:\\ 0\\.014529547921697299\ \(0\)\
\-\ bilaterally\\:\\ 0\\.014467552775896408\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.014330087584751247\ \(0\)\
\-\ metacarpal\\:\\ 0\\.014225983396809715\ \(0\)\
\-\ methotrexate\\:\\ 0\\.014041810809226864\ \(0\)\
\-\ periodic\\:\\ 0\\.014041810809226864\ \(0\)\
\-\ patterns\\:\\ 0\\.014041810809226864\ \(0\)\
\-\ trial\\:\\ 0\\.013869925823405547\ \(0\)\
\-\ begins\\:\\ 0\\.013708790882732004\ \(0\)\
\-\ mineralization\\:\\ 0\\.013413918843614106\ \(0\)\
\-\ age\\:\\ 0\\.013406754255383022\ \(0\)\
\-\ heads\\:\\ 0\\.013345186248041527\ \(0\)\
\-\ as\\:\\ 0\\.013325541297877606\ \(0\)\
\-\ erosive\\:\\ 0\\.013087239189904972\ \(0\)\
\-\ relieved\\:\\ 0\\.012967342242392363\ \(0\)\
\-\ affects\\:\\ 0\\.012536790477796572\ \(0\)\
\-\ drugs\\:\\ 0\\.012167973870475251\ \(0\)\
\-\ v\\:\\ 0\\.012083464017838677\ \(0\)\
\-\ are\\:\\ 0\\.012009008995150533\ \(0\)\
\-\ remarkable\\:\\ 0\\.011961678232141393\ \(0\)\
\-\ up\\:\\ 0\\.01184457294357847\ \(0\)\
\-\ gestational\\:\\ 0\\.011734119966302017\ \(0\)\
\-\ taking\\:\\ 0\\.011698072950903204\ \(0\)\
\-\ ulnar\\:\\ 0\\.011592861624820072\ \(0\)\
\-\ than\\:\\ 0\\.0115414889428777\ \(0\)\
\-\ patients\\:\\ 0\\.01139986906889704\ \(0\)\
\-\ advanced\\:\\ 0\\.01127027620483552\ \(0\)\
\-\ effusions\\:\\ 0\\.01124013177245616\ \(0\)\
\-\ factor\\:\\ 0\\.01124013177245616\ \(0\)\
\-\ over\\:\\ 0\\.011214652526494652\ \(0\)\
\-\ esr\\:\\ 0\\.011151757871738038\ \(0\)\
\-\ erosion\\:\\ 0\\.011122960705248024\ \(0\)\
\-\ assess\\:\\ 0\\.011038450852611448\ \(0\)\
\-\ response\\:\\ 0\\.011038450852611448\ \(0\)\
\-\ by\\:\\ 0\\.011001579148800579\ \(0\)\
\-\ five\\:\\ 0\\.010983612196819478\ \(0\)\
\-\ d\\:\\ 0\\.010983612196819478\ \(0\)\
\-\ progression\\:\\ 0\\.010956624310563563\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.010929916096554422\ \(0\)\
\-\ in\\:\\ 0\\.010860753354130281\ \(0\)\
\-\ spaces\\:\\ 0\\.010851412984480429\ \(0\)\
\-\ somewhat\\:\\ 0\\.010825767801869172\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.010403079718698372\ \(0\)\
\-\ discussion\\:\\ 0\\.010317871310809485\ \(0\)\
\-\ degree\\:\\ 0\\.010317871310809485\ \(0\)\
\-\ \\%\\:\\ 0\\.010274850687350555\ \(0\)\
\-\ is\\:\\ 0\\.010144421259518244\ \(0\)\
\-\ diagnosis\\:\\ 0\\.010114532632888761\ \(0\)\
\-\ symmetric\\:\\ 0\\.01005892664492383\ \(0\)\
\-\ those\\:\\ 0\\.010021300873219828\ \(0\)\
\-\ j\\:\\ 0\\.009947658160735147\ \(0\)\
\-\ distribution\\:\\ 0\\.009911611145336334\ \(0\)\
\-\ worse\\:\\ 0\\.009755362120036243\ \(0\)\
\-\ case\\:\\ 0\\.009636620787975623\ \(0\)\
\-\ affected\\:\\ 0\\.009529702607086967\ \(0\)\
\-\ for\\:\\ 0\\.009395723564983442\ \(0\)\
\-\ findings\\:\\ 0\\.009375448122628657\ \(0\)\
\-\ al\\:\\ 0\\.009336498899681155\ \(0\)\
\-\ pa\\:\\ 0\\.009210751053883649\ \(0\)\
\-\ references\\:\\ 0\\.009156773801705187\ \(0\)\
\-\ levels\\:\\ 0\\.00909085410637104\ \(0\)\
\-\ et\\:\\ 0\\.009013913479696602\ \(0\)\
\-\ upon\\:\\ 0\\.009001310424814665\ \(0\)\
\-\ tender\\:\\ 0\\.008939203333116055\ \(0\)\
\-\ treatment\\:\\ 0\\.008915551338148902\ \(0\)\
\-\ results\\:\\ 0\\.008890573218929502\ \(0\)\
\-\ typical\\:\\ 0\\.008831048180798962\ \(0\)\
\-\ patient\\:\\ 0\\.008830844648622556\ \(0\)\
\-\ made\\:\\ 0\\.008772866938431594\ \(0\)\
\-\ also\\:\\ 0\\.008683606152938924\ \(0\)\
\-\ similar\\:\\ 0\\.008638367574589918\ \(0\)\
\-\ 30\\:\\ 0\\.008469302413544008\ \(0\)\
\-\ active\\:\\ 0\\.008408656801662064\ \(0\)\
\-\ radiographic\\:\\ 0\\.008359186576775087\ \(0\)\
\-\ involvement\\:\\ 0\\.008072006846978909\ \(0\)\
\-\ pain\\:\\ 0\\.00806913531595929\ \(0\)\
\-\ reported\\:\\ 0\\.008028543429319102\ \(0\)\
\-\ to\\:\\ 0\\.007704837007992019\ \(0\)\
\-\ inflammatory\\:\\ 0\\.00763741222729903\ \(0\)\
\-\ now\\:\\ 0\\.007528648427066102\ \(0\)\
\-\ 10\\:\\ 0\\.007424289248316779\ \(0\)\
\-\ palpation\\:\\ 0\\.007350358454505289\ \(0\)\
\-\ cases\\:\\ 0\\.0073371414020132275\ \(0\)\
\-\ space\\:\\ 0\\.007284940739888233\ \(0\)\
\-\ disease\\:\\ 0\\.00719967804750363\ \(0\)\
\-\ positive\\:\\ 0\\.007146612346093084\ \(0\)\
\-\ often\\:\\ 0\\.007026993681751681\ \(0\)\
\-\ should\\:\\ 0\\.007021156035795876\ \(0\)\
\-\ differential\\:\\ 0\\.006992164508641571\ \(0\)\
\-\ radiographs\\:\\ 0\\.006974924848459105\ \(0\)\
\-\ known\\:\\ 0\\.0069692038259376796\ \(0\)\
\-\ and\\:\\ 0\\.006959111046348652\ \(0\)\
\-\ normal\\:\\ 0\\.006905218838139696\ \(0\)\
\-\ such\\:\\ 0\\.006884878324332094\ \(0\)\
\-\ be\\:\\ 0\\.006792560429607882\ \(0\)\
\-\ clinical\\:\\ 0\\.00677657164965465\ \(0\)\
\-\ days\\:\\ 0\\.006750191484979323\ \(0\)\
\-\ tenderness\\:\\ 0\\.006698227636292869\ \(0\)\
\-\ proximal\\:\\ 0\\.006612224695121173\ \(0\)\
\-\ negative\\:\\ 0\\.006577629281894006\ \(0\)\
\-\ loss\\:\\ 0\\.006392948898114535\ \(0\)\
\-\ not\\:\\ 0\\.006365044699700698\ \(0\)\
\-\ changes\\:\\ 0\\.006311979320193455\ \(0\)\
\-\ weeks\\:\\ 0\\.006250715868301928\ \(0\)\
\-\ following\\:\\ 0\\.006250715868301928\ \(0\)\
\-\ an\\:\\ 0\\.006091056001467679\ \(0\)\
\-\ months\\:\\ 0\\.006015312615180585\ \(0\)\
\-\ distal\\:\\ 0\\.005987831414809347\ \(0\)\
\-\ significant\\:\\ 0\\.005922286471789235\ \(0\)\
\-\ therapy\\:\\ 0\\.00588824947484694\ \(0\)\
\-\ common\\:\\ 0\\.005763575288547415\ \(0\)\
\-\ these\\:\\ 0\\.005731558484427423\ \(0\)\
\-\ more\\:\\ 0\\.005508186364206614\ \(0\)\
\-\ bone\\:\\ 0\\.005472769797576984\ \(0\)\
\-\ physical\\:\\ 0\\.005403364096858861\ \(0\)\
\-\ soft\\:\\ 0\\.005363213309261727\ \(0\)\
\-\ the\\:\\ 0\\.005344688841635018\ \(0\)\
\-\ noted\\:\\ 0\\.005220157702197407\ \(0\)\
\-\ tissue\\:\\ 0\\.005220157702197407\ \(0\)\
\-\ \\;\\:\\ 0\\.005220157702197407\ \(0\)\
\-\ or\\:\\ 0\\.005162488396720142\ \(0\)\
\-\ most\\:\\ 0\\.00508462665393834\ \(0\)\
\-\ this\\:\\ 0\\.0049543155325470776\ \(0\)\
\-\ exam\\:\\ 0\\.004838231803993655\ \(0\)\
\-\ but\\:\\ 0\\.004697173456272004\ \(0\)\
\-\ presents\\:\\ 0\\.00449908323584517\ \(0\)\
\-\ no\\:\\ 0\\.0044352791273391855\ \(0\)\
\-\ which\\:\\ 0\\.004111197389800383\ \(0\)\
\-\ that\\:\\ 0\\.0038040740426773796\ \(0\)\
\-\ \\(\\:\\ 0\\.0037235140528034047\ \(0\)\
\-\ \\)\\:\\ 0\\.003678029340790232\ \(0\)\
\-\ of\\:\\ 0\\.0033029428061285377\ \(0\)\
\-\ from\\:\\ 0\\.0032640095699850834\ \(0\)\
\-\ history\\:\\ 0\\.003041790045636813\ \(0\)\
\-\ \\.\\:\\ 0\\.0020128602941794278\ \(0\)\
\-\ with\\:\\ 0\\.001809342929225099\ \(0\)\
\-\ a\\:\\ 0\\.0010221644376768074\ \(0\)\
